Drugs / iPSC-CL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05647213 | Feb 2023 → Sep 2027 expected | congenital heart disease, heart failure, univentricular heart | HeartWorks, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iPSC-CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05647213 ↗ |
| Modality | Cell therapy | “lab-grown heart cells made from stem cells” NCT05647213 ↗ |